USD 2.46 billion
Glioblastoma Multiforme Treatment Market Size, Share, Growth Analysis, By Treatment Type (Chemotherapy, Radiation Therapy), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35D2105 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
65
|Figures:
75
Glioblastoma Multiforme Treatment Market Insights
Glioblastoma Multiforme Treatment Market size was valued at USD 2.72 Billion in 2023 and is poised to grow from USD 2.96 Billion in 2024 to USD 5.87 Billion by 2032, growing at a CAGR of 8.90% during the forecast period (2025-2032).
Owing to a variety of critical factors, the glioblastoma multiforme treatment market growth is expected to boost at a significant rate. The increasing prevalence of glioblastoma, coupled with an increased focus on research and development (R&D), is increasingly driving demand in the market. A strong product pipeline from major pharmaceutical companies, coupled with a rising incidence of brain tumors globally, is expected to drive growth in the market further. The Global Cancer Observatory reports 251,329 deaths from brain and central nervous system cancers across the globe in 2020 with 308,102 diagnoses. In 2021, the World Health Organization (WHO) reported more than 245,000 instances of brain and nervous system tumors, which requires efficient treatment options for this aggressive malignancy. However, the market is also constrained by several challenges facing it such as the expensive cost of care and the inability to come up with effective drugs. Pharmaceutical companies can't easily come up with effective drugs for GBM since it is quite aggressive, resistant to medication, and has a poor outcome. In addition, the high-priced novel drugs may limit access by patients mainly in developing countries. Despite all these challenges, there are a lot of opportunities in the glioblastoma multiforme treatment industry, especially related to creating immunotherapies, targeted therapies, and innovative therapy combinations. Due to advancements in personalized medicine and positive clinical trial results, which also open the door to increased chances of better outcomes for patients, this market has immense growth potential.
US Glioblastoma Multiforme Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Surgery
Fastest Growth
Surgery
Growth Rate
9.7% CAGR
Global Glioblastoma Multiforme Treatment Market ($ Bn)
Country Share for North America (%)
To get more reports on the above market click here to Buy The Report
Glioblastoma Multiforme Treatment Market Segmental Analysis
Global Glioblastoma Multiforme Treatment Market is segmented by treatment type, end user and region. Based on treatment type, the market is segmented into chemotherapy (temozolomide, bevacizumab, carmustine, lomustine, others), radiation therapy (external beam radiation therapy (EBRT), brachytherapy), targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors), immunotherapy (checkpoint inhibitors, vaccine therapy), tumor treating fields (TTF) therapy and surgery (craniotomy, biopsy). Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Treatment
As per the 2023 glioblastoma multiforme treatment market forecast, radiation therapy category dominated the market, with a 37.0% revenue share. This is due to higher survival rates, and as radiation therapy is prescribed as a first-line treatment or in combination with chemotherapy and surgery. Even in the case of recurrence, it is very much recommended and helpful for brain tumors. A paper by Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments, presented in April 2020, avails chemotherapeutic drugs such as temozolomide, carmustine, and bevacizumab for effective treatment regimens. Simultaneous use with temozolomide makes the tumor more radiation sensitive. Radiation is less effective without temozolomide.
However, the surgery category is expected to dominate during the forecast period. Surgery is the most common treatment used as the first line for Glioblastoma multiforme (GBM). Surgery is primarily used to resect as much of the tumor as possible with preservation of healthy brain tissue; in GBM, total removal is rarely feasible due to GBM's aggressive nature and tendency for dissemination. To limit the growth and prevent any recurrence, radiation therapy typically follows surgery to destroy remaining tumor cells. Chemotherapy then serves as an adjuvant to radiation therapy in an attempt to further attack the cancer cells and prolong survival; temozolomide is commonly used in conjunction with chemotherapy. Even though newer treatments such as immunotherapy and targeted therapies are being explored to improve outcomes in GBM, the current standard of care remains surgery, radiation, and chemotherapy.
Analysis By End Use
Based on the 2023 glioblastoma multiforme treatment market analysis, the hospitals segment had the most revenue share in 2023 and is expected to continue to hold this position throughout the forecast period. As far as patient choice in respect of healthcare accessibility and ease are concerned, patients such as hospitals. Moreover, this market sector is predicted to expand further due to the sheer volume of operations performed to treat GBM and the complexity of the treatment process. Diffusion Pharmaceuticals initiated a Phase II trial for patients with glioblastoma multiforme in July 2022 which employed advanced imaging to measure tumor oxygenation. Several companies wish to develop and commercialize new drugs to treat patients affected by neurological disorders, including glioblastoma and stroke.
Over the projection period, however, the clinics segment is expected to expand at the highest CAGR. This rise is mainly due to the growing use of non-invasive therapies such as radiation therapy and tumor-treating field therapy, especially in the management of tumors. Due to being more patient-centric with treatment alternatives showing fewer side effects as compared to the traditional method, the latest treatments have been found to gain popularity. The growing adoption of non-invasive therapies, like the ones in tumor-treating field therapy and external beam radiation therapy will significantly drive the market. To illustrate this fact, Johns Hopkins Medicine addresses brain cancer by combining radiation treatment with tumor-treating field therapy that enhances the prospects of industry development.
Global Glioblastoma Multiforme Treatment Market By End Use
To get detailed analysis on other segments, Request For Free Sample Report
Glioblastoma Multiforme Treatment Market Regional Insights
In 2023, North America had the highest share at 43.4%. The major factors driving the regional market growth are the favorable reimbursement policies, easy accessibility to quality health care facilities, rising awareness about rare conditions, and the support from the government towards the expansion of the healthcare sector. In 2022, the number of new cases of primary brain and spinal cord cancers will be predicted to reach 25,050 people in the US (14,170 men and 10,880 women). The American Cancer Society reveals that 85–90% of all primary CNS cancers occur in the brain. Moreover, 4,170 children in the US under the age of 15 had a diagnosis of brain or central nervous system cancers in 2022.
Asia-Pacific is expected to have the highest growth in the glioblastoma multiforme (GBM) treatment market throughout the projection period, with an 11.1% growth rate. Due to improved access and cost, the availability of generic temozolomide continues to drive the progression. Better economic condition is also showing increasing demands for GBM treatments because of a growing aged population. Increased investments in the healthcare sector further improve infrastructure and treatment options. Further, there are a lot of unmet needs in the region for more effective treatments of GBM, and increased awareness of the disease increases the demand for better care. The existence of a strong product pipeline, particularly treatments at the blood-brain barrier, offers promising opportunities for regional market development.
Global Glioblastoma Multiforme Treatment Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Glioblastoma Multiforme Treatment Market Dynamics
Glioblastoma Multiforme Treatment Market Drivers
Increasing Incidence of Glioblastoma Multiforme (GBM)
-
The leading cause of market growth is the increasing incidence of glioblastoma multiforme across the globe. The increasing incidence of brain tumors, particularly GBM, which is the most aggressive form of brain tumor, is due to both lifestyle choices and aging. The higher the number of patients diagnosed, the greater becomes the demand for new treatments and newer research, driving the global growth in research on GBM therapies.
Advancements in Product Pipeline and Research
-
Major advances in R&D of innovative therapies are dramatically changing the landscape of GBM treatment. New developments in the form of immunotherapies, customized therapy, and drugs with the ability to cross the blood-brain barrier may further enhance the outcome of treatment of patients with GBM. Further effectiveness will be seen as the result of current clinical studies and the growing product pipeline, facilitating easier access and tailoring treatment of GBM to the needs of each patient.
Glioblastoma Multiforme Treatment Market Restraints
Challenges in Treatment Effectiveness
-
As GBM develops very rapidly and is innately resistant to conventional treatment, GBM is one of the most challenging malignancies to treat. However, the tumor tends to recur even after chemotherapy, radiotherapy, and surgery. This resistance might be because the tumor has the ability to adapt and avoid therapy at a very rapid speed. This is the reason why the effectiveness of treatments already existing is still limited, hindering the industry's growth and preventing patients from reaching long-term survival.
High Cost of Medical Care
-
For most new drugs such as immunotherapy and targeted therapies, the development of GBM treatments is very expensive. These treatments often cost a lot, which means that individuals and health care systems incur a significant out-of-pocket price tag. This potentially might restrict access to these treatments in certain areas, especially in low and middle-income nations.
Request Free Customization of this report to help us to meet your business objectives.
Glioblastoma Multiforme Treatment Market Competitive Landscape
Companies such as Merck & Co., Novocure, and Roche lead the highly competitive glioblastoma multiforme treatment industry. To cater for the rapidly growing demand for more potent GBM treatment, these companies are focusing on innovative drugs such as immunotherapies and personalized treatment. Similarly, the market competition and the dynamic market environment with continuous innovation are further influenced by new biotechnological companies that are discovering new technologies aimed at crossing the blood-brain barrier.
Glioblastoma Multiforme Treatment Market Top Player’s Company Profiles
- Roche Holding AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Novartis AG
- Amgen Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Sanofi S.A.
- Bayer AG
- AstraZeneca plc
- Johnson & Johnson
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
- Celgene Corporation
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Ipsen S.A.
- Sumitomo Dainippon Pharma Co., Ltd.
- Karyopharm Therapeutics Inc.
Glioblastoma Multiforme Treatment Market Recent Developments
- In August 2022, Northwest Biotherapeutics' Pediatric Investigation Plan was approved by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA). This approval was an important component of the approval for new medicines like DCVax-L that adult patients required.
- In July 2021, QV Bioelectronics indicated that it would fund and support the development of their innovative GRACE implant. This implant employs electrical treatment to halt tumor and cancer cell proliferation.
- In April 2021, in a licensing agreement made with Lineage Cell Therapeutics and Immunomic Therapeutics, this latter company's technology, allogeneic VAC is to be used to treat glioblastoma multiforme and is also going to create a new oncology candidate.
Glioblastoma Multiforme Treatment Key Market Trends
- Increased Personalized Medicine Adoption: Personalized or precision medicine has emerged as a major advancement in GBM therapy. This approach helps tailor medicines according to a patient's genetic profile, thereby allowing more specialized and efficient treatment options. Advances in genetics and biomarker testing make it easier to find the treatments that have the best chance of treating the patients.
- Development of Therapies Through the Blood-Brain Barrier: Drug delivery across the blood-brain barrier (BBB) is considered one of the significant challenges in the management of GBM. Novel drug delivery technologies, including nanotechnology and other advanced technologies, are emerging to address this problem. This gives new hope for enhanced treatment outcomes and more targeted therapies against brain tumors
Glioblastoma Multiforme Treatment Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected using Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, encouraging market growth is being fueled by the increasingly developing incidence of glioblastoma multiforme and research and development. The prospect for better patient outcomes with focused treatments and cutting-edge drug delivery techniques that can cross the blood-brain barrier is bright. This notwithstanding, the market remains faced with challenges because of the aggressive nature of GBM as well as the relatively high treatment cost. Despite these challenges, this market is expected to continue growing due to the strength in the pipeline of products and continued advance in customized medicine. The upcoming years will be full of innovation and better care for GBM patients as scientists continue to make headway in overcoming current obstacles.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 2.46 billion |
| Market size value in 2031 | USD 5.66 billion |
| Growth Rate | 9.7% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Glioblastoma Multiforme Treatment Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Glioblastoma Multiforme Treatment Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Glioblastoma Multiforme Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Glioblastoma Multiforme Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Glioblastoma Multiforme Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Glioblastoma Multiforme Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
